Proactive Investors - Run By Investors For Investors

Antibe Therapeutic's Phase 2B trial safety results for pain drug ATB-346 published in British Journal of Pharmacology

A new research article in the British Journal of Pharmacology highlights the success of Antibe's 2B GI safety trial for its lead pain treatment ATB-346
Toronto-based Antibe develops safer, non-addictive medicines for pain and inflammation

Antibe Therapeutics Inc (CVE:ATE), a commercial-stage healthcare company, alerted investors Tuesday about a new research article in the British Journal of Pharmacology regarding the successful 2B GI safety trial for its lead drug ATB-346.

ATB-346 is a hydrogen sulfide-releasing derivative of naproxen, a non-steroid anti-inflammatory drug that is used to relieve pain from various conditions.

READ: British Journal of Pharmacology research article

Non-steroidal anti-inflammatory drugs such as naproxen are common pain therapies for osteoarthritis and gout, but their use is associated with a high incidence of gastrointestinal ulceration and bleeding.

The results of the safety study published in the British Journal of Pharmacology provide evidence that ATB-346 is less toxic, but as effective as naproxen in alleviating pain, according to John Wallace, Antibe’s chief scientific officer.

“We are pleased that the results of our Phase 2B GI safety study for ATB-346 have been published in BJP,” Wallace said in a statement. “The results provide unequivocal evidence for a dramatic reduction of GI toxicity of ATB‐346 as compared to naproxen, with equivalent suppression of the enzyme (cyclooxygenase; COX) that produces substances that cause pain.”

Headquartered in Toronto, Antibe develops non-addictive medicines for pain and inflammation.

Contact Ellen Kelleher at [email protected]

View full ATE profile View Profile

Antibe Therapeutics Timeline

Related Articles

April 02 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has made significant progress since it started trading on NEX.
December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
PT exercises
December 19 2018
The Californian company is a bet on an industry that is in need of transformation
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use